Pharmacogenetic Approach for the Prevention of Rivaroxaban’s ADRs: A Systematic Review and Meta-Analysis

Table 4

Genetic mutations in odds of rivaroxaban ADRs (bleeding following rivaroxaban administration).

Gene	Mutation	Description of analysis	Pooled OR (95% CI)	Heterogeneity
				I^2 (%)	p value	Model
ABCB1	rs1045642	CC vs. AA	5.46 (−5.15 to 16.08)	67.5	0.079	Fixed
ABCB1	rs1045642	AC and CC vs. AA	2.71 (−1.90 to 7.34)	0.0	0.384	Random
ABCB1	rs4148738	AA vs. CC	2.95 (−1.69 to 7.59)	0.0	0.385	Random
ABCB1	rs4148738	AC and AA vs. CC	3.08 (−6.89 to 13.06)	70.5	0.066	Fixed

ADR, adverse drug reaction; OR, odds ratio; CI, confidence interval; value was reported for the heterogeneity chi-squared test. A fixed model was used whenever value was less than 0.1.